← Home
AXIS Capital 
Insurance and reinsurance / Insurance and Professional Services
Press Releases
| Date | Press release |
|---|---|
| 2025-04-30 16:15:00 | Axis Capital Reports First Quarter Net Income Available To Common Shareholders Of $187 Million, Or $2.26 Per Diluted Common Share And Operating Income Of $261 Million, Or $3.17 Per Diluted Common Share Pembroke, bermuda--(business wire)---- $axs #insurance--axis capital holdings limited (\"axis capital\" or \"axis\" or \"the company\") (nyse: axs) today announced financial results for the first quarter ended march 31, 2025. commenting on the first quarter 2025 financial results, vince tizzio, president and ceo of axis capital said: \"axis delivered another strong quarter of consistent, profitable performance as we continued to lean into our specialty underwriting value proposition, while helping our customers navigate. |
| 2025-04-24 16:05:00 | Axis Completes Previously Announced Transaction With Enstar Pembroke, bermuda--(business wire)---- $axs #insurance--axis capital holdings limited (“axis capital” or “axis” or the “company”) (nyse: axs) and enstar group limited (“enstar”) (nasdaq: esgr) announced today that they have completed a loss portfolio transfer (“lpt”) transaction, covering reinsurance segment reserves predominantly attributable to casualty portfolios related to 2021 and prior underwriting years. the lpt reinsurance agreement covers reinsurance segment reserves totalling $3.1 billion at september 30. |
| 2025-04-08 14:03:00 | Kuehn Law Encourages Investors Of Axsome Therapeutics, Inc. To Contact Law Firm New york , april 8, 2025 /prnewswire/ -- kuehn law, pllc, a shareholder litigation law firm, is investigating whether certain officers and directors of axsome therapeutics, inc. (nasdaq: axsm) breached their fiduciary duties to shareholders. according to a federal securities lawsuit, insiders at axsome caused the company to misrepresent or fail to disclose (i) axsome’s chemistry, manufacturing, and control (\"cmc\") practices were deficient with respect to axs-07 and its manufacturing process; (ii) as a result, axsome was unlikely to submit the axs-07 nda on its initially represented timeline; (iii) the foregoing cmc issues remained unresolved at the time that the fda reviewed the axs-07 nda; (iv) accordingly, the fda was unlikely to approve the axs-07 nda; (v) as a result of all the foregoing, axsome had overstated axs-07’s regulatory and commercial prospects; and (vi) as a result, the company’s public statements were materially false and misleading at all relevant times. |
| 2025-04-02 16:15:00 | Axis Capital To Release First Quarter Financial Results On April 30, 2025 Pembroke, bermuda--(business wire)---- $axs #insurance--axis capital holdings limited (“axis capital” or the “company”) (nyse: axs) today announced that it expects to release financial results for the first quarter ended march 31, 2025 on wednesday, april 30, 2025 after the close of the financial markets. vince tizzio, president and chief executive officer, and peter vogt, chief financial officer, will host an investor teleconference, including a question and answer period, on thursday, may 1, 2025 at 8:30 a.m. et. |
| 2025-02-25 05:32:00 | Edison Issues Report On Accsys Technologies (axs) London, united kingdom--(newsfile corp. - february 25, 2025) - edison issues report on accsys technologies (aim: axs). at its investor strategy day, accsys set financial targets for the coming years, with a combined volume and revenue cagr of 14% for fy25-30e for the plant in the netherlands and the accoya usa plant (60%/40% joint venture (jv)). |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal